1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc.

LVZPF
Livzon Pharmaceutical Group Inc.US flagOther OTC
5.22
USD
- -
- -
6.06BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.47
6.55
7.84
8.77
9.22
9.5
10.01
11.23
12.91
13.49
13.36
12.84
13.49
13.16
Basic EPS, GAAP
0.58
0.61
0.74
0.9
4.78
1.16
1.39
1.83
1.9
2.04
2.1
2.24
2.27
2.42
Free Cash Flow per Basic Share
-0.57
0.06
0.53
1.04
1.1
0.85
1.46
1.62
0.63
1.96
2.61
2.62
2.88
-0.77
Dividend per Share
0.23
0.24
0.1
0.27
0.23
1.2
0.93
1.17
1.35
1.39
1.71
1.46
1.16
1.81
Book Value per Share
3.14
3.55
4.34
4.86
9.28
9.36
9.98
10.55
11.4
12.15
12.72
13.77
15.29
14.45
Tangible Book Value per Share
3.88
4.4
5.25
7.67
11.71
12.14
12.58
13.92
14.31
14.96
14.97
15.39
16.37
15.63
Basic Weighted Avg Shares
844
846
844
872
926
933
937
937
935
936
930
920
891
897
Sales/Revenue/Turnover
4,619
5,544
6,621
7,652
8,531
8,861
9,385
10,520
12,064
12,630
12,430
11,812
12,020
11,802
Operating Margin (%)
13.37
11.89
12.33
12.92
14.2
12.47
16.89
22
18.13
17.69
19.56
23.96
23.09
24.79
Depreciation Expense
169
247
311
362
359
364
385
394
445
652
840
575
574
- -
Net Income, GAAP
488
516
623
784
4,429
1,082
1,303
1,715
1,776
1,909
1,954
2,061
2,023
2,171
Effective Tax Rate (%)
16.69
15.09
18.36
17.43
21.61
16.59
15.4
14.39
13.07
16.09
20.36
17.88
15.76
17.35
Profit Margin (%)
10.56
9.31
9.4
10.25
51.91
12.21
13.88
16.3
14.72
15.12
15.72
17.45
16.83
18.4
Working Capital
651
497
423
2,660
6,949
7,102
7,580
8,544
7,748
9,591
9,179
8,795
8,898
8,828
LT Debt
550
466
1
1
1
1
- -
370
642
1,986
1,622
1,479
767
1,383
Total Equity
3,605
4,082
4,810
7,106
11,234
11,750
12,275
13,640
14,311
14,936
14,767
14,906
15,547
14,924
Return on Invested Capital (%)
12.19
11.7
12.8
12.73
9.74
7.19
9.84
13.4
11.56
10.45
10.21
12.17
12.37
12.88
Return on Capital (%)
13.14
12.25
13.57
15.83
62.95
9.78
9.94
10.49
11.94
12.67
12.77
10.99
9.34
11.08
Return on Common Equity (%)
19.63
18.26
18.68
19.85
69.05
12.5
14.41
17.83
17.29
17.34
16.84
16.82
15.39
17.57

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,504
2,410
2,237
LT Borrowings
1,466
1,433
1,368
LT Finance Leases
13
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
911
911
904
Market Capitalization
23,419
22,328
22,042

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
16,420
16,466
16,238
Cash, Cash Equivalents & STI
10,917
10,899
10,611
Accounts Receivable, Net
1,936
2,001
2,301
Inventories
1,998
1,900
1,715
Total Current Liabilities
7,625
7,235
7,410
Payables & Accruals
- -
- -
- -
ST Debt
2,504
2,410
2,237
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.94%
2.68%
4.3%
Free Cash Flow
36.16%
37.31%
6.73%
Net Income, GAAP
48.41%
3.41%
-1.84%
Sales/Revenue/Turnover
6.35%
2.91%
1.76%
Total Cash Common Dividend
59.44%
0.27%
-22.93%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,243
3,040
2,799
2,731
11,812
2025
3,181
3,091
2,904
- -
12,020
2026
2,871
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.65
- -
- -
- -
2.24
2025
0.71
- -
- -
- -
2.27
2026
0.65
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
1.46
2025
0.01
- -
- -
- -
1.16
2026
0.02
- -
- -
- -
- -

Company Description

APIChat
CEO
Daping Liu
Full Time Employees
9,067
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Headquarters Building Zhuhai People's Republic of China 519090
IPO Date
Jun 29, 2018
Website
livzon.com.cn
Similar Companies
Curaleaf Holdings, Inc. (CURA.CN)
HUTCHMED (China) Limited (HCM)
Guobang Pharma Ltd. (605507.SS)
Valiant Laboratories Limited (VALIANTLAB.BO)
Ironwood Pharmaceuticals, Inc. (IRWD)
Bausch Health Companies Inc. (BHC.TO)
Business
Livzon Pharmaceutical Group Inc. is a comprehensive pharmaceutical company headquartered in Zhuhai, China, founded in 1985. It operates primarily in the pharmaceutical manufacturing industry, offering a broad range of products that include drug preparations such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis; Laprazole sodium for injection for peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for treating endometriosis, breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection for anovulation treatment. The company also provides Perospirone Hydrochloride tablets for schizophrenia; Shenqi Fuzheng Injection aimed at fatigue and cancer treatment; anti-viral granules for upper respiratory infections and influenza; Tocilizumab injection for rheumatoid arthritis; and recombinant SARS-CoV-2 fusion protein vaccine to prevent COVID-19. Additionally, Livzon produces diagnostic reagents including nucleic acid test kits for various viruses, antibody detection kits, and interferon-gamma release assay test kits. Livzon Pharmaceutical also manufactures active pharmaceutical ingredients (APIs) certified for markets including the US and Europe, such as Vancomycin, and offers chemical medicines and microbiological preparations with a focus on advanced pharmaceutical research and development. The company targets healthcare providers and pharmaceutical distributors across China and international markets. In recent major developments, Livzon Pharmaceutical formed an exclusive licensing agreement with Neosyn Pharmaceuticals in early 2025 for the highly selective KCNQ2/3 activator NS-041, expanding its neurology-focused product pipeline. In 2025, the company initiated a significant equity buyback program, repurchasing over 16 million A shares to strengthen shareholder value. Livzon also announced the acquisition of a 64.81% stake in Vietnamese pharmaceutical firm Imexpharm, marking a substantial cross-border expansion into Southeast Asia. Furthermore, it established new governance committees to enhance ESG initiatives and remuneration frameworks, reflecting strategic organizational improvements and commitment to sustainability. These actions indicate Livzon Pharmaceutical Group's ongoing strategic focus on expanding its innovative drug portfolio, geographical footprint, and corporate governance to solidify its position in the competitive pharmaceutical industry. The company maintains strong domestic and growing international operations, continuously integrating advanced pharmaceuticals, biologics, and diagnostic technologies to serve various therapeutic areas.